Personalized, adaptive deep brain stimulation (DBS) can enhance the control of motor symptoms of Parkinson's disease (PD) compared with standard DBS, new research suggests. In a blinded randomized ...

The US Food and Drug Administration (FDA) has approved the first adaptive deep brain stimulation (aDBS) system for Parkinson’s disease (PD) that self-adjusts therapy to individual brain activity in ...

Adaptive deep-brain stimulation (DBS) using personalized neural signals improved Parkinson's motor symptoms in a pilot study. Adaptive DBS reduced the duration of symptoms by about 50% compared with ...

Chandigarh [India], April 17: Healing Hospital Chandigarh today announced the launch of Adaptive Deep Brain Stimulation (aDBS), an advanced therapy for Parkinson’s disease. With this development, the ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

The FDA approved Medtronic's BrainSense Adaptive DBS for Parkinson's, offering personalized therapy through automatic adjustments to patients' needs. The ADAPT-PD trial validated aDBS's safety and ...

The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode identifier) for people with Parkinson's disease, Medtronic announced Monday. Like ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc, a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...